Serum matrix metalloproteinase‐7, Syndecan‐1, and CA 19‐9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma
Cancer Medicine · 2024
DOI: 10.1002/cam4.70144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Doron Yablecovitch und 18 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel. Hauptthemen laut MEDLINE: Matrix Metalloproteinase 7, Syndecan-1, Carcinoma, Pancreatic Ductal, Biomarkers, Tumor. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims and Background Matrix metalloproteinase‐7 (MMP‐7) and Syndecan‐1 (SDC1) are involved in multiple functions during tumorigenesis. We aimed to evaluate the diagnostic and prognostic performance of these serum proteins, as potential biomarkers, in patients with pancreatic ductal adenocarcinoma (PDAC) and benign pancreatic cysts.
Methods
In this case–control study, patients with newly diagnosed PDAC ( N = 121) were compared with the benign cyst ( N = 66) and healthy control ( N = 48) groups. Serum MMP‐7 and SDC1 were measured by ELISA. The diagnostic accuracy of their levels for diagnosing PDAC and pancreatic cysts was computed, and their association with survival outcomes was evaluated.
Results
MMP‐7 median serum levels were significantly elevated in the PDAC (7.3 ng/mL) and cyst groups (3.7 ng/mL) compared with controls (2.9 ng/mL) ( p < 0.001 and 0.02, respectively), and also between the PDAC and cyst groups ( p < 0.001), while SDC1 median serum levels were significantly elevated in PDAC (43.3 ng/mL) compared with either cysts (30.1 ng/mL, p < 0.001) or controls (31.2 ng/mL, p < 0.001). The receiver operating characteristic curve analysis area under the curve in PDAC versus controls was 0.90 and 0.78 for MMP‐7 and SDC1, respectively, while it was 1.0 for the combination of the two and CA 19‐9 ( p < 0.001). The combination of the three biomarkers had a perfect sensitivity (100%).
Conclusions
Due to its high sensitivity, this biomarker panel has the potential to rule out PDAC in suspected cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel.
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Shalvata Mental Health Center, Hod Hasharon, Israel.
- Department of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
ORCID-Profile: Doron Yablecovitch, Ido Laish
Zitieren
APA
Yablecovitch, D., Nadler, M., Ben-Horin, S., Picard, O., Yavzori, M., Fudim, E., Duchan, M. T., Sakhnini, E., Lang, A., Lahav, M., Saker, T., Neuman, S., Selinger, L., Freitz, B., Dvir, R., Raitses-Gurevich, M., Golan, T., Levy, I., & Laish, I. (2024). Serum matrix metalloproteinase‐7, Syndecan‐1, and CA 19‐9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.70144
Vancouver
Yablecovitch D, Nadler M, Ben-Horin S, Picard O, Yavzori M, Fudim E, et al. Serum matrix metalloproteinase‐7, Syndecan‐1, and CA 19‐9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma. Cancer Medicine. 2024. doi:10.1002/cam4.70144
BibTeX
@article{Yablecovitch2024,
author = {Yablecovitch, Doron and Nadler, Moshe and Ben-Horin, Shomron and Picard, Orit and Yavzori, Miri and Fudim, Ella and Duchan, Moran Tardio and Sakhnini, Emad and Lang, Alon and Lahav, Maor and Saker, Talia and Neuman, Sandra and Selinger, Limor and Freitz, Biana and Dvir, Revital and Raitses-Gurevich, Maria and Golan, Talia and Levy, Idan and Laish, Ido},
title = {Serum matrix metalloproteinase‐7, Syndecan‐1, and CA 19‐9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70144}
}
EUVIMED